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In Brief
Makowska et al. show that several
myosin isoforms (Myo1b, Myo9b, Myo10,
and Myo18a) are overexpressed in
metastatic prostate cancer. Knockdown
of each of the myosins resulted in distinct
cell phenotypes, showing that they can
contribute to metastasis through re-
organization of the actin cytoskeleton in
addition to motor activity.
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We investigated the myosin expression profile in
prostate cancer cell lines and found that Myo1b,
Myo9b, Myo10, and Myo18a were expressed at
higher levels in cells with high metastatic potential.
Moreover, Myo1b and Myo10 were expressed at
higher levels in metastatic tumors. Using an siRNA-
based approach, we found that knockdown of each
myosin resulted in distinct phenotypes. Myo10
knockdown ablated filopodia and decreased 2D
migration speed. Myo18a knockdown increased
circumferential non-muscle myosin 2A-associated
actin filament arrays in the lamella and reduceddirec-
tional persistence of 2D migration. Myo9b knock-
down increased stress fiber formation, decreased
2Dmigrationspeed, and increaseddirectional persis-
tence. Conversely, Myo1b knockdown increased
numbers of stress fibers but did not affect 2D migra-
tion. In all cases, the cell spread area was increased
and 3D migration potential was decreased. There-
fore, myosins not only act as molecular motors but
also directly influence actin organization and cell
morphology, which can contribute to the metastatic
phenotype.
INTRODUCTION
Myosins are a large and diverse family of molecular motors
important for cell migration and motility. The human genome
encodes 39 myosin genes, subdivided into 12 different classes
(Berg et al., 2001; Peckham and Knight, 2009). Class 2 is the
largest (13 genes). Ten of these are found exclusively in muscle.
The remaining three encode the non-muscle (NM) myosin iso-
forms 2A, 2B, and 2C, which contribute to cell shape, adhesion,
and cytokinesis (Mogilner and Keren, 2009; Vicente-Manzanares
et al., 2009). Myosin isoforms in the remaining classes contribute
to a wide range of functions, including organelle trafficking,
membrane tethering, Golgi organization, actin organization,
and actin polymerization (Hartman and Spudich, 2012). Individ-
ual cell types only express a subset of myosin genes. Early2118 Cell Reports 13, 2118–2125, December 15, 2015 ª2015 The Austudies have shown that 8–11 different myosin isoforms are
co-expressed in epithelial cell lines, leukocytes, liver cells, and
myoblasts (Bement et al., 1994; Wells et al., 1997). Somemyosin
isoforms are expressed widely, whereas others (e.g., Myo7a and
Myo3) are restricted to a small tissue subset (Dose´ and Burnside,
2000; Hasson et al., 1995).
It has never been determined how variation in myosin expres-
sion profile between closely related cell types contributes to a
variation in cellular phenotype. Modulating myosin expression
could help to drive a cell toward a more migratory phenotype
and, therefore, metastasis in cancer. Here we determined the
myosin isoform expression profile in a range of prostate cell lines
and in silico and then investigated four of the overexpressed
myosin isoforms to uncover how each contribute to the more
highly metastatic phenotype of PC-3 cells (Pulukuri et al., 2005).
RESULTS
Myo1b, Myo9b, Myo10, and Myo18a Are Overexpressed
in More Highly Metastatic Cells
We analyzed myosin expression for all 26 of the non-muscle
myosin genes in the three most widely used prostate cancer
cell lines: PC-3, DU145, and LNCaP (Weber et al., 2004). PC-3
cells are considered to have a higher metastatic potential than
LNCaP cells (Aalinkeel et al., 2004). Class 2 muscle myosin
isoforms were excluded because they are not expressed in
non-muscle cells. We also analyzed a matched pair of normal
(1535NP) and cancerous (1535CT) cell lines derived from the
prostate of the same patient (Bright et al., 1997).
A core of 12 myosin genes were expressed in all cell lines
tested, as demonstrated by RT-PCR (Table S1). However,
DU145 cells additionally expressed two myosin isoforms,
Myo7a andMyo3, normally only expressed in the cochlea, retina,
testis, lung, and kidney (Hasson et al., 1995) or in the retina
and pancreas (Dose´ and Burnside, 2000) respectively, and,
therefore, we did not use these cells in further experiments,
although, for completeness, the qPCR analysis on these cells
is included (Figure S1).
Expression levels of MYO1B, MYO1D, MYO1E, MYO9B,
MYO10, and MYO18A were significantly higher in PC-3 than in
LNCaPcells byqPCR (Figure1A).MYO1BandMYO10expression
levelswerealsosignificantlyhigher in1535CT than in1535NPcells
(Figure 1B). An in silico analysis (Figure 1C) showed thatMYO1B,thors
Figure 1. Myosin Expression Profiles in
Tumors and Prostate Cancer Cell Lines
(A) Comparison of the expression levels for 12 of
the myosin isoforms expressed by LNCaP and
PC-3 cells, detected by qPCR. Data are presented
as mean ± SD (n = 3).
(B) Comparison of the expression levels for six
myosin isoforms expressed by a pair of matched
(normal [1535NP] and cancerous [1535CT]) pros-
tate cancer cell lines, detected by qPCR. Data are
presented as mean ± SD (n = 3).
(C) In silico analysis of the mRNA expression levels
for eight myosin isoforms in 171 (GEO: GSE6919)
prostate tumor samples. Data are shown as the
log2 expression ratio. Clinical tumor classification
and number of samples are indicated.
*p < 0.05, **p < 0.01, ***p < 0.001.MYO1D, andMYO10 levels were significantly higher in metastatic
tumors than in benign tissue, suggesting that this trend is also
found in vivo. MYO1E and MYO18A expression levels were also
higher in 1535CT cells compared with 1535NP cells, although
this difference was not significant, and the in silico analysis did
not show any significant differences in expression (Figure 1C).
However, the expression ofMYO18A orMYO1Emay be upregu-
lated in some tumors. MYO6 expression levels were significantly
lower in PC-3 cells compared with LNCaP (Figure 1A), lower inCell Reports 13, 2118–2125, De1535CT than in 1535NP cells (Figure 1B),
and highest in localized medium-grade tu-
mors (Figure 1C), as reported earlier (Dunn
et al., 2006; Puri et al., 2010). MYO9B
expression levelswere increased in tumors
compared with benign tissues (Figure 1C).
Levels of MYH9, the only non-muscle
myosin 2 gene we found to be expressed
in prostate cancer cells, did not change at
the mRNA level (Figure 1A) between
LNCaP and PC-3 cells or between normal,
tumor, ormetastatic samples in the in silico
analysis. Western blotting for Myo1b,
NM2A, Myo6, Myo9b, Myo10, Myo18a,
and NM2A in PC-3 and LNCaP cells (Fig-
ures 2A and 2B) showed similar trends in
protein expression levels.
In PC-3 cells, high endogenous levels of
Myo10 were associated with a high num-
ber of filopodia (Figures 2C and 2D), in
whichMyo10was localized to the tips (Fig-
ure 2F), as expected from its known role in
filopodium formation (Berg and Cheney,
2002;Berget al., 2000). In contrast, both fi-
lopodium number and Myo10 expression
levels were low in LNCaP cells (Figure 2C),
staining was diffuse, andMyo10was often
absent from filopodial tips (Figures 2E and
2F). Upregulation of Myo10 in breast can-
cer cells has been linked to expression of
mutantp53 (Arjonenetal., 2014).However,LNCaPcells are p53wild-type, andPC-3cells arep53-null (Carroll
et al., 1993), suggesting that, in this case, there is no link between
Myo10 overexpression and expression of mutant p53. In DU145
cells, which do express mutant p53, Myo10 expression is slightly
higher, and numbers of filopodia are increased compared with
LNCaP cells (Figures S1A and S1B), but both are lower compared
with PC-3 cells.
Myo1b localized to organelles in both cell types (Figures 2D
and 2E), as expected from its roles in trafficking of endosomes,cember 15, 2015 ª2015 The Authors 2119
Figure 2. Expression and Localization of
Myosin Isoforms in LNCaP and PC-3 Cells
(A and B) Example immunoblots (A) showing the
variation in expression levels for five myosin iso-
forms in PC-3 and LNCaP cells. Molecular markers
(in kilodalton) are shown on the right. Anti-Myo18a
shows a single band with a molecular weight close
to 230 kDa, suggesting that only the a isoform is
expressed (Mori et al., 2003). The results are
quantified in (B). Data are presented as mean ± SD
(n = 3). Expression levels were compared with total
p44/p42 MAPK (ERK) for all isoforms except
Myo9b, for which GAPDH was used. GAPDH gave
similar results as ERK as a loading control.
(C) Quantification of numbers of filopodia in LNCaP
and PC-3 cells (n = 20).
(D and E) Maximum intensity projection images for
PC-3 (D) and LNCaP (E) cells immunostained for
F-actin (red) and either Myo1b, Myo9b, Myo10, or
Myo18a (green). The arrows in (D) indicate Myo1b
localization within filopodia, Myo9b in actin rich
protrusions, Myo10 at filopodial tips, and Myo18 in
actin-rich lamellae. The arrows in (E) indicate
Myo1b localization to vesicles and lack of Myo9b in
actin-rich protrusions. Merged images include nu-
clear staining using DAPI (blue). Scale bar, 30 mm.
(F) Many filopodia, and Myo10 at their tips PC-3
cells, contrasted with few filopodia with lack of
Myo10 localization in LNCaP cells.
*p < 0.05, **p < 0.01, ***p < 0.001.multivesicular bodies, and lysosomes (Cordonnier et al., 2001;
Raposo et al., 1999; Salas-Cortes et al., 2005). Higher Myo1b
expression in PC-3 cells was associated with an additional local-
ization of Myo1b to actin-rich structures at the plasma mem-
brane and filopodia (Figure 2D), consistent with an earlier study
(Tang and Ostap, 2001). Myo9b andMyo18a were both enriched
in membrane ruffles/lamellipodia in PC-3 cells (Figure 2D),
consistent with Myo18a’s role in modifying actin organization
in the lamellipodium (Hsu et al., 2010) and Myo9b’s role in cell
polarity and recruitment of RhoGAP to the lamellipodium (Hanley
et al., 2010). Staining for both was diffuse in LNCaP cells.
The higher endogenous expression levels of Myo1b, Myo9b,
and Myo10 in more metastatic cell types/tissue suggested that
they all contribute to the cellular phenotype of metastatic cells.
We therefore used siRNA knockdown (KD) to determine the
effects of reducing their expression levels in PC-3 cells on cell
morphology and cell migration. We also investigated Myo18a
because the interaction of Myo18a regulates NM2A filaments
(Billington et al., 2015) and, therefore, may also influence cell
migration and phenotype.2120 Cell Reports 13, 2118–2125, December 15, 2015 ª2015 The AuthorsKnockdown of Myo1b, Myo9b,
Myo10, and Myo18a Results in
Isoform-Specific Changes in Cell
Morphology, Cell Migration, and
Actin Bundle Organization in PC-3
Cells
siRNA-mediated KD for 72 hr significantly
reduced expression levels of each myosin
isoform in PC-3 cells (Figure 3A) andaltered their morphology (Figure 3B). The spread area of the cells
increased up to 3-fold (Figure 3C). KD of Myo10, but not Myo1b,
Myo9b, or Myo18a, also significantly reduced the numbers of fi-
lopodia (Figure 3D). Although the increase in cell area in Myo10
KD cells could be explained by the reduction in filopodia, as re-
ported for COS-7 and HeLa cells (Bohil et al., 2006), it does not
explain the increased cell area for Myo1b, Myo9b, and Myo18a
KD cells, where filopodia are still present.
Myo9b and Myo10 were most important for PC-3 cell migra-
tion in 2D. Knockdown of Myo9b and Myo10 both significantly
reduced cell speed2-fold in a 2D randommigration assay (Fig-
ures 3E and 3F). Directional persistence was increased slightly
for Myo9b KD cells but unaltered for Myo10. In contrast, knock-
down of Myo1b and Myo18a did not affect speed in 2D random
migration assays (Figures 3E and 3F). Knockdown of Myo18a
significantly reduced directional persistence in 2D (Figures 3E
and 3G), indicating that these cells are less able to polarize. How-
ever, cell migration was inhibited for each myosin in a circular
invasion assay (Figure 3H) that closely mimics 3D invasion (Yu
and Machesky, 2012). Staining for F-actin in circular migration
Figure 3. Knockdown of Myosin 1b, 9b, 10,
and 18a Affects Morphology and Cell Migra-
tion of PC-3 Cells
(A) KD of Myo1b, Myo9b, Myo10, or Myo18a in
PC-3 cells analyzed by immunoblotting after 72 hr
confirms that myosin levels are reduced signifi-
cantly. Loading control: total ERK or GAPDH.
(B) Representative fields showing control and
myosin-depleted PC-3 cells stained for F-actin
using fluorescent phalloidin, obtained by tiling
using the 340 objective on the Zeiss LSM 880.
Images are shown in reverse contrast. Arrowheads
show prominent stress fibers (Myo1b KD), pe-
ripheral high-density actin staining (Myo9b KD),
central stress fiber bundles (Myo10 KD), and
increased actin in lamellae (Myo18a KD).
(C and D) Quantification of cell area (C) and number
of filopodia (D) in control and myosin KD cells (n =
20). NT, control cells treated with non-targeting
siRNA.
(E) Representative tracks for individual cells during
an overnight time-lapse microscopy experiment
for control (treated with non-targeting siRNA) and
Myo1b, Myo9b, Myo10, and Myo18a-KD cells af-
ter HGF stimulation. Each colored line represents
the track taken by an individual cell in the field.
(F and G) Quantification of speed (F) and direc-
tional persistence (G) of cell migration (n = 50 cells).
Data were plotted as box-and-whisker plots, with
whiskers showing maximum and minimum values.
(H) Circular invasion assay showing cells stained
for F-actin and nuclei (DAPI). The dashed line
marks the border of cell-free space that was
created by stoppers before their removal. Scale
bar, 100 mm and 90 mm (Myo18a KD).
(I) Magnified images of cells at the border of the
cell-free space stained for F-actin. Scale bar,
10 mm.
*p < 0.05, **p < 0.01, ***p < 0.001.assays (Figure 3I) showed an increase in actin stress fibers for
cells at the border for each myosin knockdown compared with
controls.
We also observed distinct changes in the acto-myosin
organization following KD of each myosin. Control PC-3 cells
(Figures 4A and 4B) contained few F-actin stress fibers, andCell Reports 13, 2118–2125, DeNM2A staining was mostly localized
to the lamellae. A marked increase in
centripetal F-actin fibers running parallel
to the plasma membrane in the lamella
associated with NM2A filaments was
characteristic of Myo18a KD (Figures
4A and 4B). The appearance of sparse,
long stress fibers, associated with
NM2A and extended along the length
of the cells, was characteristic of
Myo1b KD (Figures 4A–4C). A line profile
analysis of the frequency of actin bun-
dles in the lamellae of KD cells showed
that the frequency of bundles was
reduced significantly (2.1 ± 0.1 bun-dles/mm, mean ± SEM, n = 9) compared with controls (2.6 ±
0.2 bundles/mm, mean ± SEM, n = 9, p < 0.5%) (Figures 4A
and 4B), suggesting that the actin cytoskeleton is being re-
organized. Myo9b KD cells contained a distinctive actin-rich
area at the cell periphery from which NM2A was largely absent,
in addition to an increase in stress fibers (Figures 4A and 4B).cember 15, 2015 ª2015 The Authors 2121
Figure 4. Knockdown of Myosin 1b, 9b, 10,
and 18a Affects Focal Adhesion and Actin
and NM2A Organization in PC-3 Cells
(A and B) Control cells treated with non-targeting
siRNA and myosin-depleted cells co-stained for
F-actin (red) and NM2A (green) (A). An enlarged
view of the region in the boxed area in (A) is shown
in (B). Arrowheads indicate F-actin structures in KD
cells. Scale bars, 5 mm (A) and 2 mm (B).
(C) Control NT cells and myosin-depleted cells
co-stained for F-actin (red) and focal adhesions
using paxillin (green). Arrowheads indicate focal
adhesions at the ends of F-actin bundles in KD cells
Scale bar, 30 mm.
(D) Immunoblotting for phosphorylated myosin
light chain (pMLC) and ERK or GAPDH (loading
control) in control and KD cells. Quantification of
the control andMyo9b KD blot shown here showed
a 1.8-fold increase in pMLC in KD compared with
NT cells. UT, untreated.Myo10 KD cells showed loss of filopodia and the appearance
of distinctive actin bundles in the central region of the cell (Fig-
ures 4A and 4B).
Changes to the F-actin organization were associated with for-
mation of focal adhesions at the edges of the cells, consistent
with a more spread cell phenotype (Figure 4C). Knockdown of
Myo1b, Myo10, or Myo18a did not change phosphorylation
levels of myosin light chain (MLC) (Figure 4D), suggesting
that NM2A is re-organized rather than activated as a result of
their knockdown. Myo9b KD did increase MLC phosphorylation
2-fold in cells, and this is likely to contribute to the actomyosin
re-organization observed (Figure 4D).2122 Cell Reports 13, 2118–2125, December 15, 2015 ª2015 The AuthorsDISCUSSION
These data show that Myo10, Myo9b, and
Myo1b are overexpressed in more highly
metastatic cell lines and in metastatic
tissue. High levels of Myo10 in PC-3 cells
are linked to high numbers of filopodia,
and high levels of Myo9b are linked to
low levels of stress fibers. Both isoforms
contribute to amoremigratory phenotype,
as shown by immunostaining, cell migra-
tion, and KD experiments. Myo1b and
Myo18a influence cell morphology and
actin organization but have little effect
on migration in 2D, whereas all four iso-
forms inhibit cell migration in invasion
assays. Therefore, changes in expression
of several myosin isoformsmay contribute
to metastasis in prostate cancer.
Our finding that Myo10-dependent
filopodia are likely to be important in pros-
tate cancer agrees with recent similar
findings for breast cancer metastasis (Ar-
jonen et al., 2014; Cao et al., 2014) and
non-small lung cell cancer (Sun et al.,
2015). Filopodia are important but notabsolutely required for cell migration because Myo10 KD cells
canmigrate in 2D but with a reduced speed, and other cells lack-
ing filopodia can migrate (Lundquist, 2009). The increased cell
area resulting from Myo10 KD agrees with previous findings
(Bohil et al., 2006). The central actin bundles in Myo10 knock-
down cells are reminiscent of actin bundles in filopodia. Fascin
is also required for filopodial formation (Vignjevic et al., 2006),
its overexpression results in multiple filopodia (Vignjevic et al.,
2006), and fascin levels are also upregulated in prostate cancer
(Darnel et al., 2009). Myo10 KD may lead to actin bundling in the
cell body by excess (non-phosphorylated) fascin. The role of two
filopodial proteins, Myo10 and fascin, in prostate (and other)
cancers suggest that filopodium formation is key for metastasis.
Myo10 has also been implicated in integrin-mediated adhesion,
and any reduction in adhesion resulting from its KD could disrupt
signaling to the actin cytoskeleton and, therefore, indirectly
result in changes in actin organization.
High levels of Myo9b expression in PC-3 cells are likely to
contribute to their lack of stress fibers and, therefore, to enhanced
migration. The RhoGTPase-activating domain in Myo9b inhibits
Rho, reducing the downstream activity of ROCK (RhoKinase),
thereby increasing MLC phosphatase activity, reducing MLC
phosphorylation (Reinhard et al., 1995; Wirth et al., 1996), and,
therefore, reducing actin stress fiber formation. Knockdown of
Myo9b is therefore expected to increase MLC phosphorylation
and stress fiber formation, as we observed. In agreement with
our findings, a previous report has shown that cell migration
was reduced and MLC phosphorylation increased in macro-
phages isolated from Myo9b knockout mice (Hanley et al.,
2010). Myo9b has also been implicated in an increased risk of
esophageal cancer (Menke et al., 2012).
The high levels of Myo1b in PC-3 cells and effects of knock-
down on 3D invasion, cell shape, and morphology suggest that
it, too, has a role in prostate cancer. Myo1b has also been impli-
cated in non-small-cell lung cancers (Ohmura et al., 2015).
Myo1b (Myr1/MM1a; Gillespie et al., 2001) regulates actin as-
sembly in vesicular transport (post-Golgi carriers [Almeida
et al., 2011] and endocytic organelles [Cordonnier et al., 2001;
Raposo et al., 1999]), and it maintains cortical tension at the
plasma membrane, where it specifically associates with dy-
namic, non-tropomyosin-containing actin filaments (Coluccio
and Geeves, 1999; Tang and Ostap, 2001). High endogenous
levels of Myo1b in more highly metastatic cells might therefore
increase cortical tension, allowing cells to move through stiff
extracellular matrices in vivo, perhaps explaining why knock-
down of Myo1b only affects migration in 3D but not 2D.
Myo18a could contribute to metastasis in prostate cancer.
The re-organization of actin and NM2A in Myo18a KD cells
may arise from its interaction with non-muscle myosin 2 (NM2).
NM2 forms short filaments (300 nm long) containing 20 mol-
ecules (Billington et al., 2013). The assembly/disassembly of
non-muscle myosin 2 filaments is dynamic (Shutova et al.,
2014) and regulated by many different pathways (Vicente-Man-
zanares et al., 2009). Myo18a and NM2A can form mixed bipolar
filaments in vitro that are smaller that pure NM2A filaments (Bill-
ington et al., 2015). The re-organization of NM2A we observed
after knocking down Myo18a, without a change to levels of light
chain phosphorylation, supports the idea that an interaction be-
tween Myo18a and NM2A modulates NM2A filament formation
and organization in PC-3 cells.
Therefore, Myo1b, Myo9b, Myo10, and Myo18a each
contribute to the morphology and migration of more highly met-
astatic PC-3 cells, with each myosin having a specific effect on
actin organization. Misregulation of their expression in cells
with metastatic potential may allow them to work in concert to
generate a torpedo-shaped cell with multiple protrusions that
is better able to migrate through a 3D matrix and, therefore,
more able to metastasize. Many different drugs have now been
developed that can inhibit specific myosin isoforms, including
those in classes 1, 2, 5, and 6 (Bond et al., 2013). DevelopingCell Repdrugs to block specific myosin functions could be useful in pre-
venting metastasis. Importantly, these results emphasize that
myosin not only uses actin as tracks to walk along but that it is
able to actively drive actin organization in cells.
EXPERIMENTAL PROCEDURES
Cell Culture
LNCaP, DU145, and PC-3 cells (from the ATCC) were grown in RPMI 1640me-
dium with GlutaMAX (Gibco, Life Technologies) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and penicillin-streptomycin. 1535NP and
CT cells (Bright et al., 1997) were a gift from Suzanne Topalian (Johns Hopkins
University School of Medicine). They were grown in keratinocyte medium
(Gibco, Life Technologies) supplemented with 10% heat-inactivated FBS,
1% L-glutamate, antibiotics, bovine pituitary extract, and epidermal growth
factor.
Antibodies and Reagents
The antibodies used were as follows: Myo6 (H-215, Santa Cruz Biotech-
nology); Myo10 (HPA024223, Sigma); total ERK (p44/42 mitogen-activated
protein kinase [MAPK], Cell Signaling Technology); Myo18a, a gift from Prof.
Yu and Dr. Hsu (Chang Gung University, Taiwan; Hsu et al., 2010) or from
Genscript; NM2A (PRB-440P, Covance); paxillin (SAB4502553, Sigma);
Myo1b (HPA013607, Sigma); phospho-myosin light chain (Cell Signal);
Myo9b (Proteintech); and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Abcam). HRP-conjugated secondary antibodies and fluorescent
phalloidin were from Sigma, and fluorescent secondary antibodies were
from Molecular Probes.
Transfections
siGENOME SMARTpool siRNA (GE Healthcare, Dharmacon) was used to
silence myosins in PC-3 cells. Cells were seeded at a density of 20,000
cells/ml in growth media and allowed to adhere and grow overnight. Lipofect-
amine RNAiMAX reagent (Invitrogen, Life Technologies) was used for transfec-
tions. Maximum KD was achieved after 72 hr.
PCR
The RNeasy mini kit (QIAGEN) was used to extract cellular RNA. cDNA was
synthesized using avian myeloblastosis virus (AMV) reverse transcriptase.
RT-PCR was used to detect which myosin isoforms were expressed (Table
S1). Real-time PCR using SYBR Green was used to investigate the expression
levels of expressed myosins (see Table S2 for primer sequences). Data anal-
ysis was performed using a Bio-Rad system and software.
Immunoblotting
Cells were lysed (30 min, 4C) in lysis buffer (150 mM NaCl, 0.05 M Tris [pH 8],
1% Triton X-100, and 1 mM EDTA [pH 8] with protease inhibitor cocktail
(Thermo Scientific). Lysates were clarified by centrifugation, protein content
was quantified by bicinchoninic acid (BCA) assay, and then samples were
mixed with 23 Laemmli buffer for use in protein gels (4%–20% or 7.5%) and
blots. Chemiluminescence detection (Supersignal West Pico, Thermo Scien-
tific) usedmultiple exposures to ensure signal linearity. If required, membranes
were stripped using Restore western blot stripping buffer (Thermo Scientific)
and re-probed.
Immunostaining
Cells were grown on glass coverslips, fixedwith 2%paraformaldehyde in PBS,
and stained using standard procedures (Swailes et al., 2006). Cells were
imaged using a DeltaVision deconvolution microscope or Zeiss880 Airyscan.
Migration Assays
For 2D assays, cells were plated onto a glass-bottomed 96-well plates, trans-
fected with non-targeting siRNA or with myosin KD siRNA (three replicates
each), serum-starved 48 hr later for 24 hr, and then treated with hepatocyte
growth factor (HGF) (25 ng/ml) for filming. A minimum of three fields from
each replicate was selected for imaging, over 14 hr at 5-min intervals usingorts 13, 2118–2125, December 15, 2015 ª2015 The Authors 2123
differential interference contrast (DIC) optics, and a 203 lens (512 3 512 total
pixel size, 23 2 binning) on a DeltaVision system. Cell migration was analyzed
using ImageJ software (MTrackJ plugin). To perform the 3D-like circular inva-
sion assay (Yu and Machesky, 2012), cell-free space was created using cell
stoppers (Ibidi). After removing the stopper, cells were coveredwith a thin layer
of Matrigel (4 mg/ml) and normal medium and allowed to grow and migrate for
another 24–48 hr. Cells were then fixed in 2% paraformaldehyde (PFA) and
stained.
Data Analysis
Immunoblots and digitized images of immunostained cells were analyzed us-
ing ImageJ. GraphPad Prism 5.0 was used to analyze data. Data are presented
as mean ± SD for at least three separate experiments (n R 3). A two-way
ANOVA was used to compare differences between groups, and statistical sig-
nificance was accepted for p% 0.05.
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